News
Avacta doses first patient in pivotal phase 1a trial
Avacta – a company developing targeted oncology drugs and diagnostics – has announced that the first individual has been dosed with its AVA6000 candidate.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Avacta – a company developing targeted oncology drugs and diagnostics – has announced that the first individual has been dosed with its AVA6000 candidate.